Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in vari...
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
- Associated Therapies
- -
Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 126
- Registration Number
- NCT06556472
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 45
- Registration Number
- NCT06256432
- Locations
- 🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳Aster CMI Hospital, Bangalore, Karnataka, India
🇮🇳Ganesh Shankar Vidyarthi Memorial (GSVM) Medical College, Kanpur, Uttar Pradesh, India
Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT06108362
- Locations
- 🇨🇳
Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing, China
Efficacy of Continuous Terlipressin Therapy After Endoscopic Variceal Ligation
- Conditions
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2023-09-07
- Target Recruit Count
- 165
- Registration Number
- NCT06027970
- Locations
- 🇮🇳
Department of Internal Medicine, Post Graduate Institute of Medical Education and Research,, Chandigarh, India
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- River 2 Renal Corp.
- Target Recruit Count
- 95
- Registration Number
- NCT05875948
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Baylor Scott and White All Saints Medical Center, Fort Worth, Texas, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 100
- Registration Number
- NCT05315557
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India
The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Wael Elbanna Clinic
- Target Recruit Count
- 162
- Registration Number
- NCT05266534
- Locations
- 🇪🇬
Wael El Banna Clinic, Maadi, Egypt
The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourniquets:
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Wael Elbanna Clinic
- Target Recruit Count
- 99
- Registration Number
- NCT05242783
- Locations
- 🇪🇬
Wael El-Banna Clinic, Maadi, Cairo, Egypt
The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Wael Elbanna Clinic
- Target Recruit Count
- 99
- Registration Number
- NCT05170230
- Locations
- 🇪🇬
Wael El Banna Clinic, Maadi, Egypt
The Effect of Intramyometrial Injection of Terlipressin Versus Intramyometrial Injection of Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Wael Elbanna Clinic
- Target Recruit Count
- 99
- Registration Number
- NCT05154279
- Locations
- 🇪🇬
Wael El Banna Clinic, Maadi, Egypt
🇪🇬National Research center, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.